सेफाक्लोर के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें सेफाक्लोर (सेफालोस्पोरिन) के 100 इंटरैक्शन दर्ज हैं: 23 गंभीर, 15 मध्यम, 60 मामूली, और 2 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (23)

  • इमिपेनेम और सिलास्टैटिनएंटीबायोटिकगंभीर

    Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (इमिपेनेम और सिलास्टैटिन लेबल, चेतावनियां और सावधानियां)

  • एमोक्सिसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    AMOXIL is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AMOXIL or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (एमोक्सिसिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एमोक्सिसिलिन और क्लैवुलैनेटपेनिसिलिन एंटीबायोटिकगंभीर

    History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AUGMENTIN or to other beta‑lactams (e.g., penicillins or cephalosporins). (एमोक्सिसिलिन और क्लैवुलैनेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्पीसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    CONTRAINDICATIONS The use of Ampicillin is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin or to other beta-lactam antibacterial drugs. (एम्पीसिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्पीसिलिन और सल्बैक्टमपेनिसिलिन एंटीबायोटिकगंभीर

    CONTRAINDICATIONS The use of UNASYN is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (एम्पीसिलिन और सल्बैक्टम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एर्टापेनेमएंटीबायोटिकगंभीर

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नैफसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. (नैफसिलिन लेबल, चेतावनियां)

  • पाइपेरासिलिन और टैज़ोबैक्टमपेनिसिलिन एंटीबायोटिकगंभीर

    Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or betalactamase inhibitors. (पाइपेरासिलिन और टैज़ोबैक्टम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफडिनिरसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफपोडोक्सिमसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफप्रोज़िलसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफाज़ोलिनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफाड्रोक्सिलसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफिक्सिमसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफेपिमसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफैलेक्सिनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफॉक्सिटिनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफोटेटनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफोटैक्सिमसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्टाज़िडिमसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्टारोलिनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्ट्रिएक्सोनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्यूरोक्सिमसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

मध्यम इंटरैक्शन (15)

  • एज़ट्रियोनमएंटीबायोटिकमध्यम

    Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (एज़ट्रियोनम लेबल, चेतावनियां और सावधानियां)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकमध्यम

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (एथाक्रिनिक एसिड लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सासिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफाक्लोर लेबल, चेतावनियां)

  • जेंटामाइसिनएमिनोग्लाइकोसाइडमध्यम

    Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (जेंटामाइसिन लेबल, दवाओं के इंटरैक्शन)

  • टेरिफ्लुनोमाइडइम्यूनोसप्रेसेंटमध्यम

    In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (टेरिफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)

  • डाइक्लोक्सासिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफाक्लोर लेबल, चेतावनियां)

  • पेनिसिलिन Gपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफाक्लोर लेबल, चेतावनियां)

  • पेनिसिलिन Vपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफाक्लोर लेबल, चेतावनियां)

  • Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (प्रोटामिन लेबल, सावधानियां)

  • Drug Interactions When probenecid is used to elevate plasma concentrations of penicillin or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (प्रोबेनेसिड लेबल, दवाओं के इंटरैक्शन)

  • DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (प्रोबेनेसिड और कोल्चिसिन लेबल, दवाओं के इंटरैक्शन)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमध्यम

    Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (फ्यूरोसेमाइड लेबल, दवाओं के इंटरैक्शन)

  • माइकोफेनोलेटइम्यूनोसप्रेसेंटमध्यम

    Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (माइकोफेनोलेट लेबल, दवाओं के इंटरैक्शन)

  • लेफ्लुनोमाइडइम्यूनोसप्रेसेंटमध्यम

    In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (लेफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)

  • वारफेरिनएंटीकोएगुलेंट (खून पतला करने वाली दवा)मध्यम

    Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

मामूली ज़िक्र (60)

  • Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • आर्टिकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • एंटासिड (Tums, Maalox, Mylanta)बिना पर्चे की दवा (OTC)मामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • एज़ेलास्टिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • एज़ेलास्टिन और फ्लुटिकासोनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • एड्रेनालिनसिम्पैथोमिमेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • ओमेप्राज़ोल और सोडियम बाइकार्बोनेटप्रोटॉन पंप इनहिबिटरमामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • ओलोपाटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • ओलोपाटाडीन और मोमेटासोनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • कार्बिनोक्सामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • क्लेमास्टिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • क्लोबेटासोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • क्लोरफेनिरामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • ट्रायमसिनोलोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डाइफेनहाइड्रामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डाइमेनहाइड्रिनेटएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डेक्सक्लोरफेनिरामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डेक्सामेथासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डेफ्लाज़ाकॉर्टकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डेसलोराटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डेसोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डॉक्सीलामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • डॉक्सीलामिन और पाइरिडोक्सिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • निज़ाटिडीनH2 ब्लॉकरमामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • प्रिलोकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • प्रेडनिसोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • प्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • प्रोमेथाज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • फेक्सोफेनाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • फैमोटिडीनH2 ब्लॉकरमामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • फ्लुओसिनोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • फ्लुटिकासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • फ्लुटिकासोन और सैल्मेटेरोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • फ्लुड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • फ्लुनिसोलाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • बीटामेथासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • बुडेसोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • बुडेसोनाइड और फॉर्मोटेरोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • बेक्लोमेथासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • ब्यूपिवाकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • मिथाइलप्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • मेक्लिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • मेरोपेनेमएंटीबायोटिकमामूली

    Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (मेरोपेनेम लेबल, चेतावनियां और सावधानियां)

  • मोमेटासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • रैनिटिडीनH2 ब्लॉकरमामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • लिडोकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • लेवोसेटिरिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • लोराटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • साइप्रोहेप्टाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • सिक्लेसोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • सिमेटिडीनH2 ब्लॉकरमामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • सेटिरिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • सोडियम बाइकार्बोनेटएंटासिडमामूली

    Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रॉक्सीज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • हाइड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

  • हेलोबेटासोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफाक्लोर लेबल, चेतावनियां)

कोई महत्वपूर्ण इंटरैक्शन नहीं बताया गया (2)

  • एमिनोफाइलिनमिथाइलज़ैंथिनकोई इंटरैक्शन नहीं

    …Drug Interactions for information regarding table. albuterol, systemic and inhaled amoxicillin ampicillin, with or without sulbactam atenolol azithromycin caffeine, dietary ingestion cefaclor co-trimoxazole (trimethoprim and sulfamethoxazole) diltiazem dirithromycin enflurane famotidine felodipine finasteride hydrocortisone isoflurane isoniazid isradipine influenza… (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • थियोफाइलिनमिथाइलज़ैंथिनकोई इंटरैक्शन नहीं

    …amoxicillin medroxyprogesterone ampicillin, with or without methylprednisolone sulbactam metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine… (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

आप जो कुछ भी लेते हैं, उस सबके साथ सेफाक्लोर को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।